UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31

UNITED THERAPEUTICS Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$543.15+10.03 (+1.88%)

Close on Oct 19, 2026

Market cap: $24.88B
P/E (TTM): 19.4
Dividend yield: –

UNITED THERAPEUTICS Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	3,183	2,877	2,328	1,936	1,686	1,483	1,449	1,628	1,725	1,599	1,466	1,289	1,117	916	743	593	359	281
Cost of Revenue	384	310	258	152	123	108	118	199	106	73	69	126	131	119	89	68	41	27
Gross Profit	2,798	2,568	2,070	1,785	1,563	1,375	1,331	1,429	1,620	1,526	1,397	1,154	976	787	652	524	317	255
Research & Development	550	481	408	323	540	358	1,183	358	265	148	245	243	299	173	180	165	120	239
Selling, General & Admin	756	710	477	482	467	–	–	266	330	317	453	381	394	202	156	189	172	94
Total Costs & Expenses	1,690	1,500	1,143	957	1,130	890	1,636	822	910	537	767	750	824	494	425	422	333	364
Operating Income	1,493	1,377	1,185	980	556	594	-188	805	815	1,062	699	539	292	422	318	171	26	-82
Interest Expense	20	43	59	32	19	24	44	14	9.00	3.90	4.70	18	18	17	21	20	13	11
Interest & Investment Income	192	199	163	45	17	29	44	29	11	3.50	–	–	3.83	3.94	3.45	2.94	5.15	11
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.14	-0.12	-0.16	-0.14	-0.23
Other Non-Operating Income	221	162	89	-29	38	45	23	-47	-45	-1.50	345	-14	-14	19	-19	-16	-7.13	-1.67
Asset Impairment Charges	0	0	0	0	0	0	17	0	0	0	0	–	–	6.80	–	7.69	4.49	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-7.69	-4.49	-1.60
Pretax Income	1,714	1,539	1,274	951	594	639	-165	759	770	1,060	1,044	525	279	441	299	155	19	–
Income Tax Expense	379	344	290	223	118	124	-61	170	352	347	393	185	104	136	82	44	-0.70	-34
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	175	304	217	111	19	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.63	-5.29	0.14	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	-105	589	418	714	652	–	–	–	–	106	19	-49
Net Income	1,335	1,195	985	727	476	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	–	–	–	727	476	515	-105	589	418	714	652	340	175	304	218	106	19	–
EPS (Basic)(per share)	30.13	26.44	21.04	15.98	10.60	11.65	-2.39	13.54	9.50	16.29	14.17	7.06	3.49	5.84	3.81	1.89	0.37	-1.08
EPS (Diluted)(per share)	27.86	24.64	19.81	15.00	10.06	11.54	-2.39	13.39	9.31	15.25	12.72	6.28	3.28	5.71	3.67	1.78	0.35	-1.08
Shares Outstanding (Basic, Weighted)(shares)	44	45	47	46	45	44	44	44	44	44	46	48	50	52	57	56	53	46
Shares Outstanding (Diluted, Weighted)(shares)	48	49	50	49	47	45	44	44	45	47	51	54	53	53	59	60	56	46
EBITDA	1,578	1,450	1,238	1,031	606	644	-142	841	846	1,093	732	571	324	449	338	189	37	-78

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 86.1%
Operating margin: 44.4%
Net margin: 41.6%
Return on equity, FY2025: 19.7%

Financial strength

Current ratio: 5.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 296.7%

Valuation

P/E ratio: 19.4
Price to sales: 7.89
Price to book: 3.89
Dividend yield: –